Stay updated with breaking news from Progression Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 3 trial demonstrated a reduction in SARS-CoV-2 viral load in high-risk COVID-19 patients by 94% and 99% within 24 and 48 hours of treatment, respectively Median time to a negative PCR
In a first, a novel nitric oxide nasal spray was launched in India for treating Covid-19 among adults who are at high risk of progressing to severe stages of the viral disease.
Researchers in the United Kingdom have conducted an observational cohort study on hospitalized patients and have found that the degree of severity of acute coronavirus disease 2019 (COVID-19) predicts the occurrence of chronic cerebrovascular impairment. The study further suggests that the levels of cerebrovascular impairment are associated with worse cognitive, mental, and physical well-being.
SAN DIEGO , Jan. 19, 2022 -- Sorrento Therapeutics , Inc. (Nasdaq: SRNE, "Sorrento") today announced that the US Phase 2 study ( www.ClinicalTrials.gov NCT04906694) with intranasal COVI-DROPS treatment in COVID-19 outpatients has completed enrollment.
This case-control study explores the association between vaccination with mRNA COVID-19 vaccines and hospitalization for COVID-19, and, among patients hospitali